Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/15188
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSrisawat S.
dc.contributor.authorPhivthong-Ngam L.
dc.contributor.authorUnchern S.
dc.contributor.authorChantharaksri U.
dc.contributor.authorGovitrapong P.
dc.contributor.authorSanvarinda Y.
dc.date.accessioned2021-04-05T04:32:54Z-
dc.date.available2021-04-05T04:32:54Z-
dc.date.issued2003
dc.identifier.issn3051870
dc.identifier.other2-s2.0-0038809114
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/15188-
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-0038809114&doi=10.1046%2fj.1440-1681.2003.03850.x&partnerID=40&md5=614cdd7a0c2f6603f71cc13dfb8bbbf5
dc.description.abstract1. Atherosclerotic cardio- and cerebrovascular disease is a leading cause of mortality in Western countries. Aspirin-like drugs are widely used to prevent and treat these occlusive cardio- and cerebrovascular diseases. The beneficial effects of these drugs have been largely attributed to inhibition of platelet cyclo-oxygenase activity and thromboxane (TX) A2 production. We investigated the effect of an aspirin-like drug, namely indomethacin, on endothelial function, plaque and platelet aggregation and the formation of vasoactive substances during the development of atherosclerosis in cholesterol-fed rabbits. 2. Rabbits were fed 1% cholesterol (n = 8), 1% cholesterol plus 25 mg/day indomethacin (n = 8) or normal rabbit chow (control group; n = 8) for 12 weeks. Urinary excretion rates of 2,3-dinor-TXB2, 6-keto-prostaglandin (PG) F1α, 8-iso-PGF2α, and nitrate were analysed at the beginning of dietary intervention and at 4 weekly intervals thereafter. At the end of the study period, platelet aggregation, aortic plaque formation and endothelium-dependent and -independent vascular functions of isolated aortic rings ex vivo were assessed. 3. Compared with control, in the cholesterol-fed group, urinary 2,3-dinor-TXB2, 6-keto-PGF1α and 8-iso-PGF2α excretion and platelet aggregation were significantly increased (P < 0.05), but urinary excretion of nitrate was decreased (P < 0.05). Treatment with indomethacin significantly reduced platelet aggregation, urinary 2,3-dinor-TXB2, 6-keto-PGF1α, and 8-iso-PGF2α excretion (P < 0.05 vs the cholesterol-fed group) and attenuated the reduction in urinary nitrate excretion. 4. Cholesterol feeding progressively increased aortic intimal thickening and impaired endothelium-dependent vasodilator function (P < 0.05 vs control), whereas indomethacin partially prevented aortic plaque formation and restored endothelium-dependent vasodilation (P < 0.05 vs the cholesterol-fed group). 5. The present study demonstrates that indomethacin reduces the progression of atherosclerotic lesions and improves endothelium-mediated vascular responses ex vivo in cholesterol-fed rabbits. The beneficial effects of indomethacin may be due to its ability to prevent the elevation of platelet aggregation, TXA2 (measured as urinary 2,3-dinor-TXB2 excretion) and 8-iso-PGF2α, formation and to retard the decrease in endogenous nitric oxide synthesis (assessed as urinary excretion of nitrate). Despite indomethacin treatment leading to the suppression of prostacyclin biosynthesis (assessed as urinary 6-keto-PGF1α excretion), according to our data, indomethacin appears to preserve endothelial function.
dc.subject2,3 dinorthromboxane B2
dc.subject6 oxoprostaglandin F1 alpha
dc.subject8 isoprostaglandin F2 alpha
dc.subjectacetylsalicylic acid
dc.subjectcholesterol
dc.subjectindometacin
dc.subjectnitrate
dc.subjectnitric oxide
dc.subjectprostacyclin
dc.subjectprostaglandin synthase inhibitor
dc.subjectthromboxane A2
dc.subjectanimal cell
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectartery intima proliferation
dc.subjectarticle
dc.subjectatherosclerosis
dc.subjectatherosclerotic plaque
dc.subjectblood vessel function
dc.subjectcerebrovascular disease
dc.subjectcontrolled study
dc.subjectcoronary artery atherosclerosis
dc.subjectdiet
dc.subjectendothelium
dc.subjectmale
dc.subjectmortality
dc.subjectnonhuman
dc.subjectrabbit
dc.subjectthrombocyte aggregation
dc.subjecturinary excretion
dc.subjectAnimals
dc.subjectAorta, Thoracic
dc.subjectArteriosclerosis
dc.subjectCholesterol, Dietary
dc.subjectCyclooxygenase Inhibitors
dc.subjectEndothelium, Vascular
dc.subjectMale
dc.subjectRabbits
dc.subjectVasodilation
dc.titleImprovement of vascular function by chronic administration of a cyclo-oxygenase inhibitor in cholesterol-fed rabbits
dc.typeArticle
dc.rights.holderScopus
dc.identifier.bibliograpycitationClinical and Experimental Pharmacology and Physiology. Vol 30, (2003), p.405-412
dc.identifier.doi10.1046/j.1440-1681.2003.03850.x
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.